![]() ![]() Looking at the bottom line, we now estimate adjusted EPS to be $5.75, at the higher end of the company’s provided guidance, and slightly above our earlier estimate of $5.71. We now forecast sales to be $33.2 billion for the full-fiscal 2022, up 10% y-o-y, compared to our previous estimate of around $33.0 billion. We have updated our model following the Q1 release. As such, after a good Q1, MDT stock rose over 3% following the earnings release on Aug 24. Looking forward, the company revised its earnings guidance slightly upward to $5.70 per share, at mid-point of its range, compared to $5.65 earlier. ![]() However, the spread of the delta variant did impact the overall procedure volume, and it may also impact the company’s Q2 performance. This can be attributed to higher vaccination rates in the U.S. The strong performance was led by an uptick in demand for medical devices, following a rise in volume of elective surgeries. Similarly, the EPS of $1.41 was comfortably above the $1.35 per Trefis and $1.32 consensus estimates. The company reported revenues of $8.0 billion, slightly above ours and the consensus estimate of $7.9 billion. Medtronic (NYSE:MDT) recently reported its fiscal Q1 2022 results, which were better than our estimates. Price Action: MDT shares are up 2.30% at $123.47 during the market session on the last check Friday.Medtronic Stock Update.Additionally, valve thrombosis remained low out to five years for both TAVR and SAVR. The TAVR arm continued to demonstrate durable valve longevity at five years.At five years, rates of all-cause mortality were similar between TAVR with the CoreValve/Evolut platform and surgical aortic valve replacement (SAVR) (30.0% for TAVR versus 28.7% for SAVR), while rates of disabling stroke were also similar (4.1% for TAVR versus 5.8% for SAVR).Data showed from the trial demonstrated that the hemodynamic (blood flow) benefits of the CoreValve and Evolut systems were maintained at five years with a favorable safety profile and stable valve performance.Patients in the TAVR arm were compared to 796 intermediate-risk patients who were randomized to open-heart surgery.The trial evaluated two early valve generations across various valve sizes in 864 intermediate-risk symptomatic severe aortic stenosis patients. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |